# US 2025/0325540 A1 · Low dose product and method for treating diarrhea

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0325540 A1
- Document ID: US20250325540A1
- Status: Published application
- Kind: A1
- Application number: 19/075,423
- Filed: 2025-03-10
- Published: 2025-10-23
- Earliest claimed: 2016-12-23
- Assignees: Maregade Rx, LLC; White Sands Pharma LLC
- Applicants: Maregade Rx, LLC; White Sands Pharma LLC
- Inventors: Reed B. Hogan II; Joseph A. Fix
- Web page: https://patentgrep.com/patent/US20250325540A1

## CPC

- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/426: 1,3-Thiazoles
- A61P 1/12: Antidiarrhoeals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating diarrhea in a patient includes administering a dose of 2.0-7.0 mg of cetirizine and 3.0-15.0 mg of famotidine.

## Claims

### Claim 1

A method of treating diarrhea in a patient, comprising:
administering cetirizine and famotidine, wherein the cetirizine is administered in a dose of 2.0-7.0 mg per day and the famotidine is administered in a dose of 3.0-15.0 mg per day.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cetirizine is administered in a dose of 3.0-6.0 mg per day and the famotidine is administered in a dose of 5.0-14.0 mg per day.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cetirizine is administered in a dose of 4.5-5.5 mg per day and the famotidine is administered in a dose of 11.0-13.0 mg per day.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient has chronic diarrhea.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient has IBS-D.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient has acute diarrhea.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cetirizine and famotidine are administered simultaneously.

### Claim 8 (depends on 1)

The method of claim 1, wherein cetirizine and famotidine are administered once per day for at least 2 days.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cetirizine and famotidine are administered once per day for at least 7 days.

### Claim 10 (depends on 1)

The method of claim 1, wherein the patient does not have mastocytic enterocolitis

### Claim 11

A pharmaceutical composition for treating diarrhea, comprising:
2.0-7.0 mg cetirizine, and
3.0-15.0 mg famotidine.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the composition comprises 3.0-6.0 mg cetirizine and 5.0-14.0 mg famotidine.

### Claim 13 (depends on 11)

The composition of claim 11, wherein the composition comprises 4.5-5.5 mg cetirizine and 11.0-13.0 mg famotidine.

### Claim 14 (depends on 11)

The composition of claim 11, wherein the composition is an oral dosage form.

### Claim 15 (depends on 11)

The composition of claim 11, wherein composition comprises a unit dosage form.

### Claim 16 (depends on 11)

The pharmaceutical composition of claim 11, wherein the unit dosage form comprises at least one tablet or capsule.

### Claim 17 (depends on 11)

The pharmaceutical composition of claim 11, wherein the unit dosage form further comprises sodium, and glucose or a glucose-containing saccharide.

### Claim 18 (depends on 11)

The pharmaceutical composition of claim 11, wherein the unit dosage form further comprises an oral rehydration solution.

### Claim 19 (depends on 11)

The pharmaceutical composition of claim 11, wherein the oral dosage form comprises a plurality of unit dosage forms.

### Claim 20 (depends on 11)

The pharmaceutical composition of claim 11, comprising:
2.0-3.0 mg cetirizine, and
3.0-5.0 mg famotidine.

### Claim 21

A method of treating IBS-D in a patient, comprising: administering cetirizine and famotidine to the patient, wherein the cetirizine is administered in a dose of 2.0-7.0 mg per day and the famotidine is administered in a dose of 3.0-15.0 mg per day.

### Claim 22 (depends on 1)

The method of claim 1, wherein the diarrhea is selected from the group consisting of: secretory diarrhea, osmotic diarrhea, inflammatory diarrhea, functional diarrhea, malabsorbtive diarrhea, drug induced diarrhea, food intolerance diarrhea and IBS-D.
